Resonance Health Ltd (AU:RHT)
ASX:RHT
Want to see AU:RHT full AI Analyst Report?
Top Page
Resonance Health Ltd
(Sydney:RHT)
Select Model
Select Model
Rating:55Neutral
Price Target:
AU$0.04
▼(-12.00% Downside)
Action:Reiterated
Date:04/30/26
The score is held back mainly by weak financial performance, driven by negative profitability and sharply declining free cash flow despite modest revenue growth. Technicals are supportive due to price strength above moving averages, but the extremely overbought RSI raises near-term risk. Valuation is a positive factor given the low P/E.
Positive Factors
Specialized AI imaging product
A focused product suite in AI-driven MRI and image analysis builds durable competitive differentiation. Deep domain expertise and regulatory familiarity support long-term adoption by hospitals, imaging centres and pharma customers, sustaining demand over multiple years.
Negative Factors
Persistent unprofitable operations
Ongoing negative operating and net margins indicate the business has not yet reached scalable profitability. Persistent losses constrain reinvestment, limit retained capital to fund growth initiatives, and increase reliance on external funding for long-term expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialized AI imaging product
A focused product suite in AI-driven MRI and image analysis builds durable competitive differentiation. Deep domain expertise and regulatory familiarity support long-term adoption by hospitals, imaging centres and pharma customers, sustaining demand over multiple years.
Read all positive factors
Resonance Health Ltd (RHT) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$22.90M
Dividend YieldN/A
Average Volume (3M)274.25K
Price to Earnings (P/E)27.0
Beta (1Y)1.66
Revenue Growth31.36%
EPS GrowthN/A
CountryAU
Employees18
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)<0.01
Shares Outstanding477,120,240
10 Day Avg. Volume456,299
30 Day Avg. Volume274,246
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.89
Price to Sales (P/S)1.60
P/FCF Ratio22.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Resonance Health Ltd Business Overview & Revenue Model
Company Description
Resonance Health Limited is a global provider of healthcare technology and services, specializing in the design, development, and production of software-as-medical devices. The company serves markets across the Asia Pacific, Americas, Europe, Midd...
How the Company Makes Money
Resonance Health generates revenue primarily by selling access to, or use of, its medical imaging software products (including AI-enabled image analysis tools) to healthcare providers, imaging organisations, and research/pharma customers. Revenue ...
Resonance Health Ltd Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
55
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.84M | 11.07M | 8.59M | 4.40M | 3.83M | 3.78M |
| Gross Profit | 13.36M | 11.07M | 8.59M | 4.40M | 3.83M | 3.78M |
| EBITDA | 1.38M | -1.41M | -382.00K | -827.69K | -1.34M | 707.69K |
| Net Income | 769.30K | -1.73M | 169.30K | -780.00K | -1.14M | 585.86K |
Balance Sheet | ||||||
| Total Assets | 17.96M | 17.89M | 20.28M | 10.98M | 11.69M | 12.44M |
| Cash, Cash Equivalents and Short-Term Investments | 2.69M | 2.98M | 6.85M | 6.36M | 6.78M | 8.86M |
| Total Debt | 5.20M | 3.80M | 3.70M | 272.94K | 268.22K | 60.10K |
| Total Liabilities | 7.02M | 8.50M | 9.35M | 1.05M | 995.58K | 611.74K |
| Stockholders Equity | 10.94M | 9.39M | 10.93M | 9.94M | 10.69M | 11.83M |
Cash Flow | ||||||
| Free Cash Flow | 46.91K | 805.39K | 1.01M | -624.93K | -1.42M | 772.72K |
| Operating Cash Flow | 420.56K | 1.25M | 1.39M | -157.03K | -712.67K | 1.17M |
| Investing Cash Flow | -551.51K | -4.52M | -3.94M | -467.90K | -704.00K | -395.79K |
| Financing Cash Flow | -624.12K | -649.26K | 3.01M | -81.97K | -107.11K | 1.20M |
Resonance Health Ltd Technical Analysis
Positive
0.05
Price Trends
0.04
Positive
0.04
Positive
0.04
Positive
Market Momentum
<0.01
Negative
88.96
Negative
50.26
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:RHT, the sentiment is Positive. The current price of 0.05 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.04, and above the 200-day MA of 0.04, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 88.96 is Negative, neither overbought nor oversold. The STOCH value of 50.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:RHT.
Resonance Health Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | AU$18.05B | 73.47 | 72.67% | 0.24% | 30.33% | 138.71% | |
55 Neutral | AU$22.90M | 27.05 | 7.57% | ― | 31.36% | ― | |
55 Neutral | AU$74.03M | -7.46 | -23.86% | ― | -11.45% | -97.22% | |
54 Neutral | AU$780.32M | -29.99 | -35.63% | ― | 123.08% | 5.34% | |
52 Neutral | AU$42.15M | -7.79 | -14.19% | ― | 0.03% | -5.85% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | AU$63.35M | -8.12 | -59.96% | ― | ― | ― |
* Healthcare Sector Average
AU:RHT
Resonance Health Ltd
0.05
0.01
37.14%
AU:PME
Pro Medicus Limited
172.80
-98.48
-36.30%
AU:M7T
Mach7 Technologies
0.32
-0.03
-8.70%
AU:BMT
Beamtree Holdings Ltd
0.15
-0.14
-48.21%
AU:SHG
Singular Health Group Ltd
0.20
-0.18
-46.67%
AU:AYA
Artrya Limited
4.79
4.18
685.25%
Resonance Health Ltd Corporate Events
Resonance Health Flags MRI Liver Fibrosis Progress in FY26 Portfolio Update
Jun 9, 2026
Resonance Health has published an investor presentation detailing progress on its MRI Liver Fibrosis Device and outlining its FY26 portfolio plans, alongside inviting investors to a live webinar and QA with senior management on 9 June 2026. The ev...
Resonance Health Director David Fuller Acquires Initial Indirect Shareholding
May 26, 2026
Resonance Health Limited has disclosed a change in director David Fuller’s interests, with Fuller acquiring 98,701 ordinary fully paid shares in the company via an indirect holding. The shares were purchased on market on 22 May 2026 for a to...
Resonance Health Delivers Strong Cash Inflows as Trial and SaMD Pipelines Hit Record Levels
Apr 29, 2026
Resonance Health reported a strong March quarter, with cash receipts of $4.4 million, net operating cash inflow of $2.0 million, and a net cash position of $1.8 million after bank debt. The company remains operating cash flow positive year-to-date...
Resonance Health Appoints New Director With No Initial Equity Stake
Apr 27, 2026
Resonance Health Ltd has notified the ASX of the appointment of Michael Sistenich as a director effective 28 April 2026, in line with the exchange’s requirements for initial directors’ interest notices. The filing confirms that Sisteni...
Resonance Health Appoints David Fuller as Director With No Initial Shareholdings
Apr 27, 2026
Resonance Health Limited has appointed David Fuller as a director effective 28 April 2026, as disclosed in an Initial Director’s Interest Notice lodged with the ASX. The filing confirms that Fuller currently holds no direct or indirect inter...
Resonance Health Strengthens Board with Two Strategic Non-Executive Appointments
Apr 27, 2026
Resonance Health has appointed Michael Sistenich and David Fuller as non-executive directors as part of its ongoing board renewal program aimed at supporting strategic growth. The company said the additions bolster expertise in capital markets, cl...
Resonance Health Director Increases Indirect Shareholding via Off-Market Trade
Apr 1, 2026
Resonance Health Limited has disclosed a change in director Simon Panton’s relevant interests, confirming the off-market acquisition of additional ordinary fully paid shares through an entity controlled by his wife. The transaction involved ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.